UNSPSC 51271609: Clodacaine

This classification denotes an anesthetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H743H7R6YE. European Medicines Agency schedules Clodacaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06688MIG. Clodacaine generally arises in the molecular formula C16H26CLN3O.

The term CLODACAINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, list 5.) CLODACAINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clodacaine under HS 29242995 and SITC 51479. As of Q4 2014, CLODACAINE remains the US FDA Preferred Term for this commodity. Clodacaine bears US NLM identifiers UMLS ID C2699358 and NCI Concept Code C77322. SMILES: CLC1C(NC(=O)CN(CCN(CC)CC)CC)CCCC1.

UNSPSC 51271609 Clodacaine is a Commodity code that covers local anesthetic pharmaceuticals supplied through state and local cooperative purchasing agreements for healthcare facilities and government medical programs. The scope of work under this code encompasses the supply of generic local anesthetic products meeting cGMP and Drug Supply Chain Security Act (DSCSA) compliance standards, with vendors required to maintain relationships with authorized pharmaceutical wholesalers and provide detailed product specifications including National Drug Codes (NDC), strengths, dosages, and packaging configurations. State and local governments procuring under this code operate primarily through cooperative purchasing alliances rather than individual agency RFPs; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is a significant repeat buyer consolidating demand across participating state and local government healthcare facilities.

The Minnesota Multistate Cooperative Purchasing Alliance issued a Request for Proposal (S1070000015802) on January 20, 2026, with a response deadline of March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed to participating facilities in Minnesota and Oregon. The RFP weighted evaluation criteria heavily toward price competitiveness (75 percent) and fixed pricing (10 percent), with secondary weight on EDI capability, administrative compliance, and willingness to accept a 3 percent administrative fee. Awarded vendors must maintain commercial general liability coverage of $5 million per occurrence and professional liability of $2 million, carry inventory through authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, and ensure product availability by May 15, 2026 with contract effectiveness on July 1, 2026. The contract term spans two years for new responders with optional MMCAP extensions, and vendors face performance penalties of $200 to $1,500 per violation for issues including late reporting and missed onboarding timelines.